Staphylococcus aureus
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Staphylococcus aureus as ChEMBL target CHEMBL352. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Staphylococcus aureus matters
Staphylococcus aureus is reviewed as Staphylococcus aureus; the current evidence base includes 39 approved drugs, 83309 compounds, and 32915 assays, with lead potency reaching pChEMBL 9.4.
Staphylococcus aureus
Review this target as Staphylococcus aureus.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 39 approved drugs, 83309 compounds, and 32915 assays for this target. The dominant activity type is IC50. CHEMBL3814424 is the current potency anchor at pChEMBL 9.4.
Use CHEMBL3814424 as the tractability anchor when discussing potency (pChEMBL 9.4).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Staphylococcus aureus matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3814424
|
9.4 | IC50 | — |
|
|
No preferred name
CHEMBL262777
|
9.4 | IC50 | Approved |
|
|
No preferred name
CHEMBL4161555
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL186155
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL4162120
|
8.6 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
DAPTOMYCIN
CHEMBL387675
|
2003 |
|
|
MEROPENEM
CHEMBL127
|
1996 |
|
|
LEVOFLOXACIN
CHEMBL5315124
|
1996 |
|
|
DICLOFENAC
CHEMBL139
|
1988 |
|
|
NAFTIFINE HYDROCHLORIDE
CHEMBL1200493
|
1988 |
|
|
CIPROFLOXACIN
CHEMBL8
|
1987 |
|
|
METHICILLIN
CHEMBL575
|
1982 |
|
|
CEFOTAXIME
CHEMBL1730
|
1981 |
|
|
MITOMYCIN
CHEMBL105
|
1981 |
|
|
MECLOFENAMIC ACID
CHEMBL509
|
1980 |
|
|
AMOXICILLIN
CHEMBL1082
|
1974 |
|
|
KANAMYCIN
CHEMBL1384
|
1973 |
|
|
RIFAMPIN
CHEMBL374478
|
1971 |
|
|
CEPHALEXIN ANHYDROUS
CHEMBL1727
|
1971 |
|
|
MINOCYCLINE
CHEMBL1434
|
1971 |
|
|
DOXYCYCLINE
CHEMBL1200699
|
1967 |
|
|
AMPICILLIN
CHEMBL174
|
1965 |
|
|
VANCOMYCIN
CHEMBL262777
|
1964 |
|
|
ERYTHROMYCIN
CHEMBL532
|
1964 |
|
|
NOVOBIOCIN
CHEMBL36506
|
1964 |
|
|
CHLORAMPHENICOL
CHEMBL130
|
1950 |
|
|
BENZBROMARONE
CHEMBL388590
|
— |